Identification of candidate biomarkers correlated with poor prognosis of breast cancer based on bioinformatics analysis

References

• Cheng L, Huang YZ, Chen WX, et al. Cell division cycle proteinising prognostic biomarker of breast cancer. Biosci Rep. 2020;40(5):BSR20191227.
   Web of Science ®Google Scholar
• Niu T, Zhang W, Xiao W. MicroRNA regulation of cancer stem cells in the pathogenesis of breast cancer. Cancer Cell Int. 2021;21(1):31.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70:7–30.
   PubMed Web of Science ®Google Scholar
• Onitilo AA, Engel JM, Greenlee RT, et al. Breast cancer subtypes based on ER/PR and Her2 expression: comparison of clinicopathologic features and survival. Clin Med Res. 2009;7(1–2):4–13.
   PubMedGoogle Scholar
• Yang G, Jian L, Chen Q. Comprehensive analysis of expression and prognostic value of the claudin family in human breast cancer. Aging (Albany NY). 2021;13(6):8777–8796.
   Google Scholar
• Lin Y, Fu F, Lv J, et al. Identification of potential key genes for HER-2 positive breast cancer based on bioinformatics analysis. Medicine (Baltimore). 2020;99(1):e18445.
   PubMed Web of Science ®Google Scholar
• Liu S, Liu X, Wu J, et al. Identification of candidate biomarkers correlated with the pathogenesis and prognosis of breast cancer via integrated bioinformatics analysis. Medicine (Baltimore). 2020;99(49):e23153.
   PubMed Web of Science ®Google Scholar
• Wei L, Jin Z, Yang S, et al. TCGA-assembler 2: software pipeline for retrieval and processing of TCGA/CPTAC data. Bioinformatics. 2018;34(9):1615–1617.
   PubMed Web of Science ®Google Scholar
• Zhao H, Jiang A, Yu M, et al. Identification of biomarkers correlated with diagnosis and prognosis of endometrial cancer using bioinformatics analysis. J Cell Biochem. 2020;121(12):4908–4921.
   PubMed Web of Science ®Google Scholar
• Gene Ontology Consortium. The Gene Ontology (GO) project in 2006. Nucleic Acids Res. 2006;34(90001):D322–6.
   PubMedGoogle Scholar
• Kanehisa M, Goto S. KEGG: Kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 2000;28(1):27–30.
   PubMed Web of Science ®Google Scholar
• Wang X, Yue J, Ren X, et al. Modularity analysis based on predicted protein-protein interactions provides new insights into pathogenicity and cellular process of Escherichia coli O157:H7. Theor Biol Med Model. 2011;8(1):47.
   PubMedGoogle Scholar
• Song W, Ren J, Wang C, et al. Analysis of Circular RNA-related competing endogenous RNA identifies the immune-related risk signature for colorectal cancer. Front Genet. 2020;11:505.
   PubMed Web of Science ®Google Scholar
• Cai Y, Mei J, Xiao Z, et al. Identification of five hub genes as monitoring biomarkers for breast cancer metastasis in silico. Hereditas. 2019;156(1):20.
   PubMedGoogle Scholar
• Baade P. Geographical variation in breast cancer outcomes. Int J Environ Res Public Health. 2017;14(5):523.
   Web of Science ®Google Scholar
• Liang Y, Zhang H, Song X, et al. Metastatic heterogeneity of breast cancer: molecular mechanism and potential therapeutic targets. Semin Cancer Biol. 2020;60:14–27.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7–34.
   PubMed Web of Science ®Google Scholar
• Du R, Huang C, Liu K, et al. Targeting AURKA in Cancer: molecular mechanisms and opportunities for Cancer therapy. Mol Cancer. 2021;20:15.
   PubMed Web of Science ®Google Scholar
• Carvalhal S, Ribeiro SA, Arocena M, et al. The nucleoporin ALADIN regulates Aurora A localization to ensure robust mitotic spindle formation. Mol Biol Cell. 2015;26(19):3424–3438.
   PubMed Web of Science ®Google Scholar
• de Martino M, Shariat SF, Hofbauer SL, et al. Aurora A Kinase as a diagnostic urinary marker for urothelial bladder cancer. World J Urol. 2015;33(1):105–110.
   PubMed Web of Science ®Google Scholar
• Lei Y, Yan S, Ming-De L, et al. Prognostic significance of Aurora-A expression in human bladder cancer. Acta Histochem. 2011;113(5):514–518.
   PubMed Web of Science ®Google Scholar
• Matarasso N, Bar-Shira A, Rozovski U, et al. Functional analysis of the Aurora Kinase A Ile31 allelic variant in human prostate. Neoplasia. 2007;9(9):707–IN25.
   PubMed Web of Science ®Google Scholar
• Buschhorn HM, Klein RR, Chambers SM, et al. Aurora-A over-expression in high-grade PIN lesions and prostate cancer. Prostate. 2005;64(4):341–346.
   PubMed Web of Science ®Google Scholar
• Lentini L, Amato A, Schillaci T, et al. Aurora-A transcriptional silencing and vincristine treatment show a synergistic effect in human tumor cells. Oncol Res. 2008;17(3):115–125.
   PubMed Web of Science ®Google Scholar
• Koyuncu D, Sharma U, Goka ET, et al. Spindle assembly checkpoint gene BUB1B is essential in breast cancer cell survival. Breast Cancer Res Treat. 2021;185(2):331–341.
   PubMed Web of Science ®Google Scholar
• Brynychova V, Ehrlichova M, Hlavac V, et al. Genetic and functional analyses do not explain the association of high PRC1 expression with poor survival of breast carcinoma patients. Biomed Pharmacother. 2016;83:857–864.
   PubMed Web of Science ®Google Scholar
• Zhang B, Shi X, Xu G, et al. Elevated PRC1 in gastric carcinoma exerts oncogenic function and is targeted by piperlongumine in a p53-dependent manner. J Cell Mol Med. 2017;21(7):1329–1341.
   PubMed Web of Science ®Google Scholar
• Luo HW, Chen QB, Wan YP, et al. Protein regulator of cytokinesis 1 overexpression predicts biochemical recurrence in men with prostate cancer. Biomed Pharmacother. 2016;78:116–120.
   PubMed Web of Science ®Google Scholar
• Yun HJ, Cho YH, Moon Y, et al. Transcriptional targeting of gene expression in breast cancer by the promoters of protein regulator of cytokinesis 1 and ribonuclease reductase 2. Exp Mol Med. 2008;40(3):345–353.
   PubMed Web of Science ®Google Scholar
• Liu J, Wen Y, Liu Z, et al. VPS33B modulates c-Myc/p53/miR-192-3p to target CCNB1 suppressing the growth of non-small cell lung cancer. Mol Ther Nucleic Acids. 2021;23:324–335.
   PubMedGoogle Scholar
• Fei F, Qu J, Liu K, et al. The subcellular location of cyclin B1 and CDC25 associated with the formation of polyploid giant cancer cells and their clinicopathological significance. Lab Invest. 2019;99(4):483–498.
   PubMed Web of Science ®Google Scholar
• Wang L, Xia Y, Chen T, et al. Sanyang Xuedai enhances the radiosensitivity of human non-small cell lung cancer cells via increasing iNOS/NO production. Biomed Pharmacother. 2018;102:618–625.
   PubMed Web of Science ®Google Scholar
• Monteiro LS, Diniz-Freitas M, Warnakulasuriya S, et al. Prognostic Significance of Cyclins A2, B1, D1, and E1 and CCND1 numerical aberrations in oral squamous cell carcinomas. Anal Cell Pathol (Amst). 2018;2018:7253510.
   PubMedGoogle Scholar
• Wang W, Shen XB, Jia W, et al. The p53/miR-193a/EGFR feedback loop function as a driving force for non-small cell lung carcinoma tumorigenesis. Ther Adv Med Oncol. 2019;11:1758835919850665.
   Web of Science ®Google Scholar
• Egloff AM, Weissfeld J, Land SR, et al. Evaluation of anticyclin B1 serum antibody as a diagnostic and prognostic biomarker for lung cancer. Ann N Y Acad Sci. 2005;1062(1):29–40.
   PubMedGoogle Scholar
• Gao ZY, Yu F, Jia HX, et al. ASPM predicts poor prognosis and regulates cell proliferation in bladder cancer. Kaohsiung J Med Sci. 2020;36(12):1021–1029.
   PubMed Web of Science ®Google Scholar
• Wang WY, Hsu CC, Wang TY, et al. A gene expression signature of epithelial tubulogenesis and a role for ASPM in pancreatic tumor progression. Gastroenterology. 2013;145(5):1110–1120.
   PubMed Web of Science ®Google Scholar
• Hsu CC, Liao WY, Chan TS, et al. The differential distributions of ASPM isoforms and their roles in Wnt signaling, cell cycle progression, and pancreatic cancer prognosis. J Pathol. 2019;249(4):498–508.
   PubMed Web of Science ®Google Scholar
• Lin SY, Pan HW, Liu SH, et al. ASPM is a novel marker for vascular invasion, early recurrence, and poor prognosis of hepatocellular carcinoma. Clin Cancer Res. 2008;14(15):4814–4820.
   PubMed Web of Science ®Google Scholar
• Alsiary R, Bruning-Richardson A, Bond J, et al. Deregulation of microcephalin and ASPM expression are correlated with epithelial ovarian cancer progression. PLoS One. 2014;9(5):e97059.
   PubMed Web of Science ®Google Scholar
• Bikeye SN, Colin C, Marie Y, et al. ASPM-associated stem cell proliferation is involved in malignant progression of gliomas and constitutes an attractive therapeutic target. Cancer Cell Int. 2010;10(1):1.
   PubMedGoogle Scholar
• Xie JJ, Zhuo YJ, Zheng Y, et al. High expression of ASPM correlates with tumor progression and predicts poor outcome in patients with prostate cancer. Int Urol Nephrol. 2017;49(5):817–823.
   PubMed Web of Science ®Google Scholar
• Turnbull AK, Arthur LM, Renshaw L, et al. Accurate prediction and validation of response to endocrine therapy in breast cancer. J Clin Oncol. 2015;33(20):2270–2278.
   PubMed Web of Science ®Google Scholar
• McHugh T, Zou J, Volkov VA, et al. The depolymerase activity of MCAK shows a graded response to Aurora B kinase phosphorylation through allosteric regulation. J Cell Sci. 2019;132(4):jcs228353.
   Web of Science ®Google Scholar
• Andrews PD, Ovechkina Y, Morrice N, et al. Aurora B regulates MCAK at the mitotic centromere. Dev Cell. 2004;6(2):253–268.
   PubMed Web of Science ®Google Scholar
• Lan W, Zhang X, Kline-Smith SL, et al. Aurora B phosphorylates centromeric MCAK and regulates its localization and microtubule depolymerization activity. Curr Biol. 2004;14(4):273–286.
   PubMed Web of Science ®Google Scholar
• Bie L, Zhao G, Wang YP, et al. Kinesin family member 2C (KIF2C/MCAK) is a novel marker for prognosis in human gliomas. Clin Neurol Neurosurg. 2012;114(4):356–360.
   PubMed Web of Science ®Google Scholar
• Ishikawa K, Kamohara Y, Tanaka F, et al. Mitotic centromere-associated kinesin is a novel marker for prognosis and lymph node metastasis in colorectal cancer. Br J Cancer. 2008;98(11):1824–1829.
   PubMed Web of Science ®Google Scholar
• Nakamura Y, Tanaka F, Haraguchi N, et al. Clinicopathological and biological significance of mitotic centromere-associated kinesin overexpression in human gastric cancer. Br J Cancer. 2007;97(4):543–549.
   PubMed Web of Science ®Google Scholar
• Heidebrecht HJ, Buck F, Steinmann J, et al. p100: a novel proliferation-associated nuclear protein specifically restricted to cell cycle phases S, G2, and M. Blood. 1997;90(1):226–233.
   PubMed Web of Science ®Google Scholar
• Hsu CW, Chen YC, Su HH, et al. Targeting TPX2 suppresses the tumorigenesis of hepatocellular carcinoma cells resulting in arrested mitotic phase progression and increased genomic instability. J Cancer. 2017;8(8):1378–1394.
   PubMed Web of Science ®Google Scholar
• Liang B, Jia C, Huang Y, et al. TPX2 level correlates with hepatocellular carcinoma cell proliferation, apoptosis, and EMT. Dig Dis Sci. 2015;60(8):2360–2372.
   PubMed Web of Science ®Google Scholar
• Liu HC, Zhang Y, Wang XL, et al. Upregulation of the TPX2 gene is associated with enhanced tumor malignance of esophageal squamous cell carcinoma. Biomed Pharmacother. 2013;67(8):751–755.
   PubMed Web of Science ®Google Scholar
• Mills CA, Suzuki A, Arceci A, et al. Nucleolar and spindle-associated protein 1 (NUSAP1) interacts with a SUMO E3 ligase complex during chromosome segregation. J Biol Chem. 2017;292(42):17178–17189.
   PubMed Web of Science ®Google Scholar
• Tang Y, Zhang Y, Hu X. Identification of potential hub genes related to diagnosis and prognosis of hepatitis b virus-related hepatocellular carcinoma via integrated bioinformatics analysis. Biomed Res Int. 2020;2020:4251761.
   PubMed Web of Science ®Google Scholar
• Deng JL, Xu YH, Wang G. Identification of potential crucial genes and key pathways in breast cancer using bioinformatic analysis. Front Genet. 2019;10:695.
   PubMed Web of Science ®Google Scholar
• Zhang R, Xu J, Zhao J, et al. Proliferation and invasion of colon cancer cells are suppressed by knockdown of TOP2A. J Cell Biochem. 2018;119(9):7256–7263.
   PubMed Web of Science ®Google Scholar
• Liu HQ, Zhang SL, Song S. HER-2/neu and TOPIIa expression in gastric cancer reflect disease severity. Hepatogastroenterology. 2012;59:1290–1293.
   PubMedGoogle Scholar
• Shen J, Yu S, Sun X, et al. Identification of key biomarkers associated with development and prognosis in patients with ovarian carcinoma: evidence from bioinformatic analysis. J Ovarian Res. 2019;12(1):110.
   PubMed Web of Science ®Google Scholar
• Yu H, Xu Z, Guo M, et al. FOXM1 modulates docetaxel resistance in prostate cancer by regulating KIF20A. Cancer Cell Int. 2020;20(1):545.
   PubMed Web of Science ®Google Scholar
• He Q, Meng J, Liu S, et al. Long non-coding RNA UCA1 upregulates KIF20A expression to promote cell proliferation and invasion via sponging miR-204 in cervical cancer. Cell Cycle. 2020;19(19):2486–2495.
   PubMed Web of Science ®Google Scholar
• Song Z, Huang Y, Zhao Y, et al. The identification of potential biomarkers and biological pathways in prostate cancer. J Cancer. 2019;10(6):1398–1408.
   PubMed Web of Science ®Google Scholar
• Shi C, Huang D, Lu N, et al. Aberrantly activated Gli2-KIF20A axis is crucial for growth of hepatocellular carcinoma and predicts poor prognosis. Oncotarget. 2016;7(18):26206–26219.
   PubMedGoogle Scholar
• Khongkow P, Gomes AR, Gong C, et al. Paclitaxel targets FOXM1 to regulate KIF20A in mitotic catastrophe and breast cancer paclitaxel resistance. Oncogene. 2016;35(8):990–1002.
   PubMed Web of Science ®Google Scholar
• Nordlund P, Reichard P. Ribonucleotide reductases. Annu Rev Biochem. 2006;75(1):681–706.
   PubMedGoogle Scholar
• Jin CY, Du L, Nuerlan AH, et al. High expression of RRM2 as an independent predictive factor of poor prognosis in patients with lung adenocarcinoma. Aging (Albany NY). 2020;13(3):3518–3535.
   PubMedGoogle Scholar
• Grolmusz VK, Karaszi K, Micsik T, et al. Cell cycle dependent RRM2 may serve as proliferation marker and pharmaceutical target in adrenocortical cancer. Am J Cancer Res. 2016;6:2041–2053.
   PubMed Web of Science ®Google Scholar
• Grossi F, Dal Bello MG, Salvi S, et al. Expression of ribonucleotide reductase subunit-2 and thymidylate synthase correlates with poor prognosis in patients with resected stages I-III non-small cell lung cancer. Dis Markers. 2015;2015:302649.
   PubMed Web of Science ®Google Scholar
• Lu AG, Feng H, Wang PX, et al. Emerging roles of the ribonucleotide reductase M2 in colorectal cancer and ultraviolet-induced DNA damage repair. World J Gastroenterol. 2012;18(34):4704–4713.
   PubMed Web of Science ®Google Scholar
• Hsu NY, Wu JY, Liu X, et al. Expression status of ribonucleotide reductase small subunits hRRM2/p53R2 as prognostic biomarkers in stage I and II non-small cell lung cancer. Anticancer Res. 2011;31:3475–3481.
   PubMed Web of Science ®Google Scholar
• Fatkhutdinov N, Sproesser K, Krepler C, et al. Targeting RRM2 and Mutant BRAF is a novel combinatorial strategy for melanoma. Mol Cancer Res. 2016;14(9):767–775.
   PubMed Web of Science ®Google Scholar
• Huang R, Zhang J, Li M, et al. The Role of Peroxisome Proliferator-Activated Receptors (PPARs) in Pan-Cancer. PPAR Res. 2020;2020:6527564.
   PubMed Web of Science ®Google Scholar
• Bandera Merchan B, Tinahones FJ, Macias-Gonzalez M. Commonalities in the Association between PPARG and Vitamin D Related with Obesity and Carcinogenesis. PPAR Res. 2016;2016:2308249.
   PubMed Web of Science ®Google Scholar
• Fujita M, Yagami T, Fujio M, et al. Cytotoxicity of troglitazone through PPARgamma-independent pathway and p38 MAPK pathway in renal cell carcinoma. Cancer Lett. 2011;312(2):219–227.
   PubMed Web of Science ®Google Scholar
• Plissonnier ML, Fauconnet S, Bittard H, et al. Insights on distinct pathways of thiazolidinediones (PPARgamma ligand)-promoted apoptosis in TRAIL-sensitive or -resistant malignant urothelial cells. Int J Cancer. 2010;127(8):1769–1784.
   PubMed Web of Science ®Google Scholar
• Vallee A, Lecarpentier Y, Vallee JN. Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/beta-catenin pathway. J Exp Clin Cancer Res. 2019;38(1):323.
   PubMedGoogle Scholar
• Galbraith LCA, Mui E, Nixon C, et al. PPAR-gamma induced AKT3 expression increases levels of mitochondrial biogenesis driving prostate cancer. Oncogene. 2021;40(13):2355–2366.
   PubMed Web of Science ®Google Scholar
• Shen D, Fang Y, Zhou F, et al. The inhibitory effect of silencing CDCA3 on migration and proliferation in bladder urothelial carcinoma. Cancer Cell Int. 2021;21(1):257.
   PubMed Web of Science ®Google Scholar
• Adams MN, Burgess JT, He Y, et al. Expression of CDCA3 is a prognostic biomarker and potential therapeutic target in non-small cell lung cancer. J Thorac Oncol. 2017;12(7):1071–1084.
   PubMed Web of Science ®Google Scholar
• Perez-Pena J, Alcaraz-Sanabria A, Nieto-Jimenez C, et al. Mitotic read-out genes confer poor outcome in luminal A breast cancer tumors. Oncotarget. 2017;8(13):21733–21740.
   PubMedGoogle Scholar
• Endo H, Ikeda K, Urano T, et al. Terf/TRIM17 stimulates degradation of kinetochore protein ZWINT and regulates cell proliferation. J Biochem. 2012;151(2):139–144.
   PubMed Web of Science ®Google Scholar
• Yuan W, Xie S, Wang M, et al. Bioinformatic analysis of prognostic value of ZW10 interacting protein in lung cancer. Onco Targets Ther. 2018;11:1683–1695.
   PubMed Web of Science ®Google Scholar
• Ying H, Xu Z, Chen M, et al. Overexpression of Zwint predicts poor prognosis and promotes the proliferation of hepatocellular carcinoma by regulating cell-cycle-related proteins. Onco Targets Ther. 2018;11:689–702.
   PubMed Web of Science ®Google Scholar
• Zhou G, Shen M, Zhang Z. ZW10 Binding Factor (ZWINT), a direct target of mir-204, predicts poor survival and promotes proliferation in breast cancer. Med Sci Monit. 2020;26:e921659.
   PubMed Web of Science ®Google Scholar
• Williamson A, Wickliffe KE, Mellone BG, et al. Identification of a physiological E2 module for the human anaphase-promoting complex. Proc Natl Acad Sci U S A. 2009;106(43):18213–18218.
   PubMed Web of Science ®Google Scholar
• Brown NG, Watson ER, Weissmann F, et al. Mechanism of polyubiquitination by human anaphase-promoting complex: RING repurposing for ubiquitin chain assembly. Mol Cell. 2014;56(2):246–260.
   PubMed Web of Science ®Google Scholar
• Li Z, Wang Y, Li Y, et al. Ube2s stabilizes beta-Catenin through K11-linked polyubiquitination to promote mesendoderm specification and colorectal cancer development. Cell Death Dis. 2018;9(5):456.
   PubMedGoogle Scholar
• Yoshimura S, Kasamatsu A, Nakashima D, et al. UBE2S associated with OSCC proliferation by promotion of P21 degradation via the ubiquitin-proteasome system. Biochem Biophys Res Commun. 2017;485(4):483–498.
   PubMed Web of Science ®Google Scholar
• Ma Y, Li K, Li S, et al. Prognostic value of ubiquitin-conjugating enzyme E2 S overexpression in hepatocellular carcinoma. Int J Biol Macromol. 2018;119:225–231.
   PubMed Web of Science ®Google Scholar
• Pan YH, Yang M, Liu LP, et al. UBE2S enhances the ubiquitination of p53 and exerts oncogenic activities in hepatocellular carcinoma. Biochem Biophys Res Commun. 2018;503(2):895–902.
   PubMed Web of Science ®Google Scholar
• Lin TH, Hsu WH, Tsai PH, et al. Dietary flavonoids, luteolin and quercetin, inhibit invasion of cervical cancer by reduction of UBE2S through epithelial-mesenchymal transition signaling. Food Funct. 2017;8(4):1558–1568.
   PubMed Web of Science ®Google Scholar